Report Overview

Canadas Oncological therapeutics market size stood at around USD 3.93 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Over the past decade, Significant sales growth and increasing treatment costs observed in the Canadian oncology market. Sales have almost tripled, treatment costs have nearly doubled, and drugs with 28-day treatment costs over $10,000 now represent one-third of total sales. With an aging population expected to increase demand for cancer therapies, and a strong pipeline of oncology medicines under development, this fast-growing market is expected to continue to be an important consideration for Canadian patients, prescribers, and payers in years to come. The cancer diagnostics and profiling markets are growing, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy.



Market Drivers

Sales of oncology medicines in Canada have nearly tripled over the past decade, placing Canada fourth among the PMPRB11 countries in terms of growth in the oncology market. the major market drivers are Ease in regulatory approval, Increased healthcare spending for cancer, the rising prevalence of cancer, Strong R&D initiatives from key players. As the market grows, an increasing share is captured by more expensive therapies, EDRDs, and biologics, the increase in the cost of cancer treatment, along with drug prices, has resulted in the growth of the overall market.